{"id":866724,"date":"2025-07-07T07:04:35","date_gmt":"2025-07-07T11:04:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/"},"modified":"2025-07-07T07:04:35","modified_gmt":"2025-07-07T11:04:35","slug":"unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/","title":{"rendered":"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference"},"content":{"rendered":"
\n

LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (\u201cUnicycive\u201d or the \u201cCompany\u201d) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET.<\/p>\n

A link to the webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations<\/a>.<\/p>\n

\n About\u00a0Unicycive Therapeutics<\/strong>\n <\/p>\n

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive\u2019s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit\u00a0Unicycive.com<\/a>\u00a0and follow us on\u00a0LinkedIn<\/a>\u00a0and\u00a0X<\/a>.<\/p>\n

\n Investor Contact:<\/strong>\n <\/p>\n

\n Kevin Gardner<\/strong>
\n
LifeSci Advisors
kgardner@lifesciadvisors.com<\/a><\/p>\n

\n Media Contact:<\/strong>
\n
\n Rachel Visi<\/strong>
\n
Real Chemistry
redery@realchemistry.com<\/a><\/p>\n

SOURCE: Unicycive Therapeutics, Inc.<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (\u201cUnicycive\u201d or the \u201cCompany\u201d) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET. A link to the webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. About\u00a0Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are … <\/p>\n

Continue reading “Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-866724","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nUnicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (\u201cUnicycive\u201d or the \u201cCompany\u201d) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET. A link to the webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. About\u00a0Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are … Continue reading "Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-07T11:04:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTE5OCM3MDMyMTY1IzIyMTA3NjM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference\",\"datePublished\":\"2025-07-07T11:04:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/\"},\"wordCount\":224,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4OTE5OCM3MDMyMTY1IzIyMTA3NjM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/\",\"name\":\"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4OTE5OCM3MDMyMTY1IzIyMTA3NjM=\",\"datePublished\":\"2025-07-07T11:04:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4OTE5OCM3MDMyMTY1IzIyMTA3NjM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ4OTE5OCM3MDMyMTY1IzIyMTA3NjM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - Market Newsdesk","og_description":"LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) — Unicycive Therapeutics, Inc. (\u201cUnicycive\u201d or the \u201cCompany\u201d) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET. A link to the webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations. About\u00a0Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive\u2019s lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are … Continue reading \"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2025-07-07T11:04:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTE5OCM3MDMyMTY1IzIyMTA3NjM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference","datePublished":"2025-07-07T11:04:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/"},"wordCount":224,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTE5OCM3MDMyMTY1IzIyMTA3NjM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/","name":"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTE5OCM3MDMyMTY1IzIyMTA3NjM=","datePublished":"2025-07-07T11:04:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTE5OCM3MDMyMTY1IzIyMTA3NjM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ4OTE5OCM3MDMyMTY1IzIyMTA3NjM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/unicycive-therapeutics-to-present-at-the-h-c-wainwright-4th-annual-kidney-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866724","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=866724"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/866724\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=866724"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=866724"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=866724"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}